Progression of GIST

Charles D. Blanke, M.D., F.A.C.P.

Oregon Health & Science University: Link
Associate Professor of Medicine, Hematology/Oncology
GIST Research: Gastrointestinal Oncology GISTs are wholly resistant to standard chemotherapy. The discovery that they frequently respond when exposed to targeted biologic therapies was one of the most important cancer findings in the last 50 years. The overwhelming majority of patients with incurable GISTs benefit from imatinib therapy, with most achieving true shrinkage and another substantial fraction experiencing cessation of tumor growth for a prolonged period. Indeed, the average response to imatinib lasts for over two years. Unfortunately, some GISTs are resistant to imatinib treatment from the start (primary resistance) and some initially benefit from therapy and then later progress (secondary resistance). Somewhere between 5 and 12% of patients have tumors that are initially resistant, essentially progressing immediately upon starting therapy. The percentage that will develop secondary resistance is not known, but many fail at about two years, with a small fraction progressing on drug much later.
Experts have theorized different mechanisms are responsible for the two different forms of resistance, but little is truly known about why patients fail in either setting. Treating physicians may take the type of resistance into account, making subsequent decisions based on how the patient did originally when treated with imatinib and when he or she failed.

Interestingly, primary resistance is often seen in patients with mutations in exon 9 of the KIT gene or exon 18 of the PDGFR gene, as well as in patients with no observable mutations (“wild-type” patients). Secondary resistance is commonly seen in patients with pre-treatment mutations in exon 11 of KIT, the most common pattern of mutation seen. Work done by Heinrich, Corless, and others has shown patients with primary resistance have the same mutation found before and after imatinib therapy. Patients with late resistance, however, acquire new mutations, ones which are inherently resistant to imatinib.

Luckily, patients progressing on imatinib have several therapeutic options. Patients being treated with 400 milligrams per day should be serially increased to 800 milligrams daily. This simple strategy helps about one-third of patients. Patients who fail 800 milligrams of imatinib are potential candidates for sunitinib, a new tyrosine kinase inhibitor that also has anti-angiogenic effects. While most patients do not experience major objective shrinkage with sunitinib, patients given the drug live substantially longer, and they are free from GIST progression for longer periods than those not given this drug. Patients progressing on sunitinib may be candidates for an experimental drug and can rarely be considered for salvage surgery (surgery in the setting of failing a TKI is not often successful).

Progression of GIST is a serious problem that is increasingly being recognized as a long-term issue, even in those who initially do very well on imatinib mesylate. There are numerous options for these patients, however, and planning their treatment should take place at an experienced center with a multidisciplinary team of GIST experts.

10 Comments

  1. Bill Plante: But in those states, or other battleground states, do you think that the Ryan effect is likely to continue?

  2. Good response time in receiving package.

  3. This really is extremely decent- Thank you so much and even continue this very good work.

  4. Does your website have a contact page? I’m having trouble locating it but, I’d like to
    send you an email. I’ve got some recommendations
    for your blog you might be interested in hearing.
    Either way, great blog and I look forward to seeing it grow over time.

  5. Many websites let you register totally free of
    cost and definately will charge around the basis of the time you would spend using their live cams.
    The demonstration occurred after Bailey hired Kevin Melvoin-Berg of Weird Chicago Tours to produce
    a presentation on sexual fetishes. As to the naughty ones, these come upfront and recognize their desire
    for things that usually are not so sinless.

  6. Expédition très rapide ! exactement comme décrit , arrivé ici dans le temps! merci beaucoup!

  7. Many websites enable you to register absolutely free of cost and definately will charge about the basis in the time spent utilizing
    their live cams. However, logically or practically
    speaking, should you are losing interest of the
    routine hectic schedule of labor and not being able to
    fulfill your fantasies well enough, then the need in the hour would be to enroll yourself into
    a web-based adult chat room to satisfy your urge to have
    sex in probably the most convenient way. Customer services facilities are
    necessary so that you are capable to ask for support or help if ever you encounter some technical difficulties.

  8. “Ok.” Sambil mengemas, sempat kami bergurau senda . Nasib sebelah bilik dia, bilik lain jauh dan tidak mengganggu . Setelah siap semua , dia bergegas ke biliknya. Aku mengiringinya ke pintu, belum sempat dia memegang tomnol pintu aku mencapai tangannya. Dia terkejut dengan tindakan drastik aku. Wajah nakalku ditenung pelik.

  9. Buying and selling real estate notes can be considered a profitable
    niche. Even though you are going to have to cover a commission by using one,
    I would strongly advise that you simply get the help of an advert real estate broker.
    Its current portfolio carries a diverse variety of properties in Alabama, Georgia, Florida, North Carolina, South Carolina, Texas, Tennessee and also other states.

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>